#Nexsphere
LightNews LightNews
bluebird350.bsky.social
Good news: FDA approved an innovative non-surgical treatment for arthritis pain in the knee.
NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'
/PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable...
www.prnewswire.com
March 7, 2025 at 5:59 PM
newsen.bsky.social
NEXTBIOMEDICAL Grants Asahi Intecc Exclusive Rights for Nexsphere-F™ in Japan#Japan#Tokyo#NEXTBIOMEDICAL#Nexsphere-F#ASAHI_INTECC
NEXTBIOMEDICAL Grants Asahi Intecc Exclusive Rights for Nexsphere-F™ in Japan
NEXTBIOMEDICAL has signed a significant agreement with Asahi Intecc, granting exclusive distribution of Nexsphere-F™ in Japan, enhancing market entry.
third-news.com
April 9, 2026 at 1:43 PM
newsen.bsky.social
NEXTBIOMEDICAL's Nexsphere-F™ Gains Health Canada Approval for Pain Management#South_Korea#Seoul#NEXTBIOMEDICAL#Nexsphere-F™#Health_Canada
NEXTBIOMEDICAL's Nexsphere-F™ Gains Health Canada Approval for Pain Management
NEXTBIOMEDICAL CO., LTD. announces that their innovative product, Nexsphere-F™, has received approval from Health Canada for managing musculoskeletal pain.
third-news.com
January 29, 2026 at 2:22 PM
newsen.bsky.social
NEXTBIOMEDICAL Initiates Pivotal Trial for Nexsphere-F™, Targeting Knee Osteoarthritis#South_Korea#Seoul#Osteoarthritis#NEXTBIOMEDICAL#Nexsphere-F™
NEXTBIOMEDICAL Initiates Pivotal Trial for Nexsphere-F™, Targeting Knee Osteoarthritis
NEXTBIOMEDICAL has started a significant U.S. clinical trial for Nexsphere-F™, aimed at treating knee osteoarthritis pain through innovative microsphere technology.
third-news.com
October 13, 2025 at 1:40 PM
jpn-equities225.bsky.social
📊 #7747 アサヒインテック
韓国社との塞栓剤独占販売契約を締結

・慢性疼痛治療用「Nexsphere-F」の日本独占販売権獲得
・薬事承認後、保険収載目指す（5年契約）
・欧州では既に販売実績あり
・当期業績への影響なし

→ 判断: 中立⚖️
新治療領域参入は将来性あるが、承認・収載時期不明で短期的インパクト限定

#日本株 #医療機器 #カテーテル
April 9, 2026 at 10:10 PM
newsen.bsky.social
NEXTBIOMEDICAL Showcases Innovative Solutions at CIRSE 2026: A Landmark Presence in Interventional Radiology#South_Korea#Seoul#Nexsphere-F#Nexsphere#CIRSE
NEXTBIOMEDICAL Showcases Innovative Solutions at CIRSE 2026: A Landmark Presence in Interventional Radiology
NEXTBIOMEDICAL made a significant impact at CIRSE 2026, with an extensive exhibition and Learning Center focusing on innovative embolic agents and clinical collaborations.
third-news.com
September 14, 2026 at 1:09 PM
newsarea.bsky.social
Nexsphere-FTM Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain

SEOUL, South Korea, July 6, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Radiology, the leading…
Nexsphere-FTM Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain
SEOUL, South Korea, July 6, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Radiology, the leading peer-reviewed journal in radiology and medical imaging with an impact factor of 17.6, has published clini...
news-area.com
July 7, 2026 at 1:29 AM
longtail-news.bsky.social
Feed: "Medical Device Network"
By: Annabel Kartal Allen on Monday, July 6, 2026
Local artery blocking device cuts knee osteoarthritis pain by 57%, study reveals
NextBiomedical's fast-resorbable microspheres, Nexsphere-F lowered knee osteoarthritis pain in a study on standard treatment non-responders.
www.medicaldevice-network.com
July 7, 2026 at 12:01 AM
newsen.bsky.social
Nexsphere-F Clinical Study Shows Promising Results for Knee Osteoarthritis Pain Relief#South_Korea#Seoul#Osteoarthritis#NEXTBIOMEDICAL#Nexsphere-F
Nexsphere-F Clinical Study Shows Promising Results for Knee Osteoarthritis Pain Relief
A new clinical study published in the journal Radiology illustrates significant pain reduction in knee osteoarthritis patients using Nexsphere-F, showcasing a 57% decrease.
third-news.com
July 6, 2026 at 1:17 PM
l2plabs.bsky.social
Nexsphere-F™ Clinical Study Published in Radiology, Showing 57% Reduction in Knee Osteoarthritis Pain
SEOUL, South Korea, July 6, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Radiology, the leading peer-reviewed journal in radiology and medical imaging with an impact factor of 17.6, has...
dlvr.it
July 6, 2026 at 1:02 PM
bluebird350.bsky.social
New non-surgical treatment for arthritis pain in the knee was just approved by FDA.
NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'
/PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product 'Nexsphere-F™,' a resorbable...
www.prnewswire.com
March 12, 2025 at 12:12 AM
sptimes.bsky.social
NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR
Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating…
dlvr.it
March 17, 2025 at 2:16 PM
sptimes.bsky.social
NEXTBIOMEDICAL Secures FDA Breakthrough Device Designation for Innovative Resorbable Microsphere 'Nexsphere-F™'
Pioneering a Paradigm Shift in Pain Treatment, Accelerating Global Market Expansion SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a leading developer of cutting-edge Devices, announced that its groundbreaking product…
dlvr.it
March 6, 2025 at 3:17 PM
longtail-news.bsky.social
Feed: "EUROPE SAYS"
Published on Saturday, April 11, 2026
NEXTBIOMEDICAL secures exclusive distribution agreement for Nexsphere-F™ in Japan
April 10, 2026 | Friday | News
www.europesays.com
April 11, 2026 at 5:00 AM
jpn-equities225.bsky.social
📊 #7747 朝日医疗
与韩国公司签署栓塞剂独家销售合同

・获得"Nexsphere-F"日本独家销售权（慢性疼痛TAME治疗）
・药事批准后5年合同期
・欧洲三国已有销售实绩
・对当期业绩无影响

→ 中立⚖️
新治疗领域具有未来性，但审批时间及销售规模不明，短期影响有限

#日股 #医疗器械
April 9, 2026 at 10:10 PM
jpn-equities225.bsky.social
📊 #7747 Asahi Intecc
Signed exclusive sales contract for embolization agent with Korean firm

・Japan exclusive rights for "Nexsphere-F" (TAME chronic pain treatment)
・5-year contract post regulatory approval & reimbursement
・Already marketed in Europe (France, Germany, Italy)
・No current period e...
April 9, 2026 at 10:10 PM
newsen.bsky.social
NEXTBIOMEDICAL's Nexsphere-F Clinical Results Highlight its Efficacy in Joint Pain Treatment#South_Korea#Seoul#NEXTBIOMEDICAL#joint_pain#Nexsphere-F
NEXTBIOMEDICAL's Nexsphere-F Clinical Results Highlight its Efficacy in Joint Pain Treatment
Nexsphere-F™, a novel embolic agent developed by NEXTBIOMEDICAL, shows remarkable safety and effectiveness in reducing joint pain in a new clinical study, demonstrating promising results.
third-news.com
March 17, 2025 at 1:33 PM
newsen.bsky.social
NEXTBIOMEDICAL's Nexsphere-F™ Earns FDA Breakthrough Designation for Pain Management#South_Korea#Seoul#NEXTBIOMEDICAL#Nexsphere-F™#Breakthrough_Device
NEXTBIOMEDICAL's Nexsphere-F™ Earns FDA Breakthrough Designation for Pain Management
NEXTBIOMEDICAL has made strides in pain management with Nexsphere-F™, now recognized by the FDA as a breakthrough device for treating osteoarthritis.
third-news.com
March 6, 2025 at 2:47 PM
newsen.bsky.social
NEXTBIOMEDICAL Announces FDA IDE Approval for Nexsphere-F™ in Knee Osteoarthritis Treatment#South_Korea#Seoul#NEXTBIOMEDICAL#Nexsphere-F™#GAE
NEXTBIOMEDICAL Announces FDA IDE Approval for Nexsphere-F™ in Knee Osteoarthritis Treatment
NEXTBIOMEDICAL has received FDA IDE approval for Nexsphere-F™, aimed at treating knee osteoarthritis, initiating the U.S. RESORB trial.
third-news.com
January 15, 2025 at 2:40 PM
news0.bsky.social
が廃棄物処理法の改正案を閣議決定し、"ヤード"の規制強化へ 🌟 許可制を導入することで、火災や騒音問題を防ぐ狙いがあるそうです 🚮
🌸 イスラエルとレバノンの間で緊張が高まっているニュースもありました 🌪️ ネタニヤフ首相が早期にレバノンと直接交渉を始めることを内閣に指示したそうです 💬
🌸 最後に、ポジティブなニュースとしては、朝日インテックが塞栓剤「Ｎｅｘｓｐｈｅｒｅ－Ｆ」で日本独占販売契約を締結したそうです 💊
🌸🎉 ニュースは常に更新されていますので、最新の情報をチェックすることが大切です 📺👀
#最新ニュース #国際協力銀行 #プロ野球 #京都 #リズム天国 #環境省 #イスラエル
April 9, 2026 at 11:40 PM
labnews.bsky.social
NEXTBIOMEDICAL erhält Health-Canada-Zulassung für Nexsphere-F™ bei muskuloskelettaler Schmerz-Embolisation

Seoul – Das südkoreanische Medizintechnikunternehmen NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650) hat von Health Canada die Zulassung für Nexsphere-F™ erhalten. Das neuartige, schnell…
NEXTBIOMEDICAL erhält Health-Canada-Zulassung für Nexsphere-F™ bei muskuloskelettaler Schmerz-Embolisation
Seoul – Das südkoreanische Medizintechnikunternehmen NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650) hat von Health Canada die Zulassung für Nexsphere-F™ erhalten. Das neuartige, schnell resorbierbare Mikrosphären-Präparat ist für die Embolisation bei muskuloskelettalen Schmerzen zugelassen, insbesondere bei arthrosebedingten Beschwerden. Nexsphere-F™ besteht aus resorbierbaren Mikrosphären, die abnorme Blutgefäße, die mit Arthroseschmerzen assoziiert sind, temporär verschließen. Innerhalb von 2 bis 8 Stunden nach dem Eingriff führt dies zur Nekrose schmerzerzeugender Nervenzellen und damit zu einer effektiven Schmerzreduktion.
labnews.io
January 29, 2026 at 5:08 PM
l2plabs.bsky.social
NEXTBIOMEDICAL Secures Health Canada Approval for Nexsphere-F™ in Musculoskeletal Pain Embolization
SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that Nexsphere-F™, the company's novel fast resorbable microsphere for musculoskeletal pain embolization has received...
dlvr.it
January 29, 2026 at 2:01 PM
l2plabs.bsky.social
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain
RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, today announced the enrollment of the first...
dlvr.it
October 13, 2025 at 1:03 PM
byteseu.bsky.social
NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan

https://www.byteseu.com/1928078/

SEOUL, South Korea, April 9, 2026 /PRNewswire/ — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced today that it has …
NEXTBIOMEDICAL Secures Exclusive Distribution Agreement for Nexsphere-F™ in Japan - Bytes Europe
SEOUL, South Korea, April 9, 2026 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea,
www.byteseu.com
April 9, 2026 at 1:45 PM
byteseu.bsky.social
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain

https://www.byteseu.com/1448591/

NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain NEXTBIOMEDICAL Announces …
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain - Bytes Europe
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain
www.byteseu.com
October 14, 2025 at 3:00 AM